Vertex Pharmaceuticals (VRTX) Non-Current Assets (2009 - 2026)

Vertex Pharmaceuticals' Non-Current Assets history runs 18 years deep, the most recent figure standing at $14.8 billion for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 14.62% year-over-year to $14.8 billion in Q1 2026; TTM through Mar 2026 was $57.1 billion, a 15.5% increase from a year earlier, with the FY2025 full-year figure at $14.4 billion, up 11.64% from the prior year.
• Non-Current Assets advanced to $14.8 billion in Q1 2026 per VRTX's latest filing, from $14.4 billion in the prior quarter.
• Across five years, Non-Current Assets topped out at $14.8 billion in Q1 2026 and bottomed at $3.9 billion in Q1 2022.
• The 5-year median for Non-Current Assets is $10.6 billion (2024), against an average of $9.6 billion.
• Across the five-year window, Non-Current Assets rose 8.36% in 2022 and soared 76.89% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $4.9 billion in 2022, then jumped by 74.65% to $8.6 billion in 2023, then soared by 50.67% to $12.9 billion in 2024, then grew by 11.64% to $14.4 billion in 2025, then climbed by 2.16% to $14.8 billion in 2026.
• Per Business Quant, the three latest VRTX Non-Current Assets figures stand at $14.8 billion (Q1 2026), $14.4 billion (Q4 2025), and $14.3 billion (Q3 2025).